Eosinophilic Esophagitis
Conditions
Keywords
eosinophilic esophagitis, eotaxin 3, major basic protein, interleukin 5, interleukin 13, transforming growth factor beta 1, high-resolution manometry, Gastrointestinal Quality of Life index
Brief summary
The aim of the project is to assess the correlation between the results of high-resolution oesophageal manometry and specific biomarkers of inflammation (eotaxin 3, major basic protein, IL-5, IL-13, TGF-beta1) with symptoms of dysphagia, endoscopic and histological features and the assessment of quality of life in patients with eosinophilic esophagitis. Research hypothesis: The results of high resolution esophageal manometry (HRM) and specific inflammatory biomarkers correlate with symptoms of dysphagia, endoscopic and histological features, and assessment of quality of life in patients with eosinophilic oesophagitis. HRM, along with the determination of specific inflammatory biomarkers present in the peripheral blood, may serve as a less invasive method of assessing the effectiveness of the treatment of eosinophilic oesophagitis in relation to the currently used endoscopic examinations.
Interventions
DIAGNOSTIC_TESTHigh-resolution manometry
The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls.
DIAGNOSTIC_TESTSerum biomarkers
The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls.
DIAGNOSTIC_TESTGastrointestinal Quality of Life index
The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls.
The parameters of high-resolution esophageal manometry and serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs.
Sponsors
Wroclaw Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients over 18 years of age, * patients referred for endoscopic diagnostics due to dysphagia.
Exclusion criteria
* already diagnosed chronic diseases with possible eosinophilic infiltration of the gastrointestinal tract (eosinophilic esophagitis, eosinophilic gastroenteritis, Crohn's disease, celiac disease), * rheumatological, dermatological and genetic disorders with possible peripheral eosinophilia, * dysphagia caused by a diagnosed neoplastic infiltration of the esophagus.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| High-resolution manometry | 3 months | The parameters of high-resolution esophageal manometry will be compared between EoE patients and controls. |
| Serum biomarkers | 3 months | The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared between EoE patients and controls. |
| Gastrointestinal Quality of Life index | 3 months | The Gastrointestinal Quality of Life index (GIQLI) will be compared between EoE patients and controls. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| High-resolution manometry in the group of patients with EoE | 3 months | The parameters of high-resolution esophageal manometry will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs. |
| Serum biomarkers in the group of patients with EoE | 3 months | The serum levels of IL-5, IL-13, TGF-β1, MBP and eotaxin 3 will be compared in the group of patients with EoE at enrollment in the project and after 3 months of treatment with PPIs. |
Countries
Poland
Outcome results
None listed